The Mayo Clinic Cancer Center (MCCC) considers the Developmental Funds to be one of the most critical components of Cancer Center Support Grant (CCSG) support. Together with institutionally derived MCCC discretionary funds end the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, end the initiation of research projects or generation of pilot data for subsequent peer review grant applications.Given the smell size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the lest funding period, institutionally-derived MCCC discretionary funds end philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, end ell funding for instrumentation end new laboratory set-up costs. Processes are firmly established in the MCCC to solicit end review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities end, in the case of shared resource development, the unambiguous need of investigators with peer reviewed funding. The same level of funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty. ? Pilot projects - to eneble the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to ensure the scientific vitality of MCCC investigators end programs Support of Staff Investigators- MCCC is requesting partial salary support for three Staff Investigators. Neither of these three individuals have e leadership position within the Center, its programs, or its shared resources however, they are judged to be critical by the MCCC leadership to the operation of the Cancer Center for different reasons. The MCCC's Developmental Fund request represents approximately 5.8% of the direct costs requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682953
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$299,918
Indirect Cost
$111,446
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications